Etherna

The company offers catalog mRNAs from stock for immediate supply.

Trusted partner for scalable GMP grade mRNA manufacturing with robust QC, documentation, and batch release to support clinical applications

The company offers high-purity, research-grade mRNA designed for scalable and reliable results.

etherna and UHasselt partner to develop mRNA-LNP therapy for autoimmune diseases focusing on multiple sclerosis research.

etherna appoints Tony de Fougerolles as Chair. Tony brings deep mRNA and LNP expertise to lead etherna’s next phase.

etherna lists upcoming events and conferences and describes advancements in mRNA and LNP technologies.

The page provides answers to frequently asked questions.

The company's news covers advancements in mRNA and LNP technologies and events it attends.

Florence is an expert in mucosal T cell development and function with over 20 years of immunology and immune-oncology experience including 7 years of life science industry expertise.

etherna's board of directors guides its mission.

etherna's management team brings expertise and leadership to its innovations.

etherna specializes in developing nucleic acid-based medicines and has a team of over 75 experts.

The company's team works on discoveries and advancements in mRNA and LNP.

The page identifies etherna's founding and current shareholders among its key investors and describes strategic partnerships driving innovation.

The company says it responds to contact form inquiries within two business days and provides info@etherna.be as an email contact.

etherna offers custom drug delivery platforms for tailored LNP drug delivery solutions.